Oncology and Hematology - Prova Education

Episodes 1-16 of 62

CME/CE Meeting
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
December 08, 2024
Singapore
1.50 credits Learn more
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
CME/CE Live Broadcast
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
December 18, 2024
12:00 PM - 01:30 PM ET
1.50 credits Learn more
How Antibody-Based Therapies Are Revolutionizing Its Management
How Antibody-Based Therapies Are Revolutionizing Its Management
CME/CE
How Antibody-Based Therapies Are Revolutionizing Its Management
0.25 credits
- Caroline Piatek, MD
- Irina Murakhovskaya, MD
0.25 credits
Mutational Testing to Guide Therapy in CLL: Why and When
Mutational Testing to Guide Therapy in CLL: Why and When
MinuteCE®
Mutational Testing to Guide Therapy in CLL: Why and When
1.25 program credits
- Talha Munir, PhD
1.25 program credits
MinuteCE®
Fixed-Duration: A Patient-Captivating Standard of Care in CLL
1.25 credits 10 episodes
- Talha Munir, PhD
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 credits 10 episodes
Combination Therapy for CLL: What Evidence Do We Have?
Combination Therapy for CLL: What Evidence Do We Have?
MinuteCE®
Combination Therapy for CLL: What Evidence Do We Have?
1.25 program credits
- William Wierda, MD, PhD
1.25 program credits
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
MinuteCE®
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
1.25 program credits
- William Wierda, MD, PhD
1.25 program credits
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
MinuteCE®
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
MinuteCE®
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
1.25 program credits
- Thomas Kipps, MD, PhD
1.25 program credits
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
MinuteCE®
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
Risk-Stratification in Newly Diagnosed CLL
Risk-Stratification in Newly Diagnosed CLL
MinuteCE®
Risk-Stratification in Newly Diagnosed CLL
1.25 program credits
- Thomas Kipps, MD, PhD
1.25 program credits
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
MinuteCE®
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
MinuteCE®
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
MRD Testing to Guide Treatment Considerations in CLL
MRD Testing to Guide Treatment Considerations in CLL
MinuteCE®
MRD Testing to Guide Treatment Considerations in CLL
1.25 program credits
- Talha Munir, PhD
1.25 program credits
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
CME/CE
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
1.00 credit
- Josep Tabernero, MD, PhD
- Sara Lonardi, MD
- Zev A. Wainberg, MD
1.00 credit
Advancements in GU Cancers: Key Data from AUA 2024
Advancements in GU Cancers: Key Data from AUA 2024
CME/CE
Advancements in GU Cancers: Key Data from AUA 2024
0.50 credits
- Jason Hafron, MD
- Carissa Chu. MD
0.50 credits

Prev
1
2
3
4
Next

1/4